Advertisement
The offering is being underwritten on a firm commitment basis by Feltl and Company, Inc.
Net proceeds of this offering will be used to fund certain operating expenses and development costs as the Company pursues FDA 510(k) clearance of its ProUroScan(TM) prostate imaging system and to retire certain short-term liabilities.
Advertisement
A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This press release does not constitute an offer to sell or the solicitation of an offer to buy the shares of common stock or any other securities, nor will there be any sale of the shares of common stock or any other securities in any state of jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer, if at all, will be made only by means of a prospectus forming a part of the effective registration statement.
Copies of the final prospectus relating to the offering may be obtained from Feltl and Company, Inc., 225 South Sixth Street, Suite 4200, Minneapolis, MN 55402.
About ProUroCare Medical Inc.
ProUroCare Medical Inc. is a development stage company engaged in the business of developing for market innovative products for the detection and characterization of male urological prostate disease. The Company's primary focus is currently the ProUroScan prostate imaging system, which is now in clinical trials.
SOURCE ProUroCare Medical Inc.
